Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease
Juliana Isa Beraldo, Acaris Benetti, Flávio Araújo Borges-Júnior, Daniel F Arruda-Junior, Flavia Letícia Martins, Leonardo Jensen, Rafael Dariolli, Maria Heloisa Shimizu, Antonio C Seguro, Weverton M Luchi, Adriana C C Girardi, Juliana Isa Beraldo, Acaris Benetti, Flávio Araújo Borges-Júnior, Daniel F Arruda-Junior, Flavia Letícia Martins, Leonardo Jensen, Rafael Dariolli, Maria Heloisa Shimizu, Antonio C Seguro, Weverton M Luchi, Adriana C C Girardi
Abstract
Dipeptidyl peptidase IV (DPPIV) inhibitors are antidiabetic agents that exert renoprotective actions independently of glucose lowering. Cardiac dysfunction is one of the main outcomes of chronic kidney disease (CKD); however, the effects of DPPIV inhibition on cardiac impairment during CKD progression remain elusive. This study investigated whether DPPIV inhibition mitigates cardiac dysfunction and remodeling in rats with a 5/6 renal ablation and evaluated if these effects are associated with changes in the cardiac renin-angiotensin system (RAS). To this end, male Wistar rats underwent a 5/6 nephrectomy (Nx) or sham operation, followed by an 8-week treatment period with the DPPIV inhibitor sitagliptin (IDPPIV) or vehicle. Nx rats had lower glomerular filtration rate, overt albuminuria and higher blood pressure compared to sham rats, whereas CKD progression was attenuated in Nx + IDPPIV rats. Additionally, Nx rats exhibited cardiac hypertrophy and fibrosis, which were associated with higher cardiac DPPIV activity and expression. The sitagliptin treatment prevented cardiac fibrosis and mitigated cardiac hypertrophy. The isovolumic relaxation time (IRVT) was higher in Nx than in sham rats, which was suggestive of CKD-associated-diastolic dysfunction. Sitagliptin significantly attenuated the increase in IRVT. Levels of angiotensin II (Ang II) in the heart tissue from Nx rats were higher while those of angiotensin-(1-7) Ang-(1-7) were lower than that in sham rats. This cardiac hormonal imbalance was completely prevented by sitagliptin. Collectively, these results suggest that DPPIV inhibition may delay the onset of cardiovascular impairment in CKD. Furthermore, these findings strengthen the hypothesis that a crosstalk between DPPIV and the renin-angiotensin system plays a role in the pathophysiology of cardiorenal syndromes.
Keywords: 5/6 renal ablation; cardiorenal syndromes; dipeptidyl peptidase IV; renin-angiotensin system.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
- Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369:1317–1326. doi: 10.1056/NEJMoa1307684.
- Udell J.A., Bhatt D.L., Braunwald E., Cavender M.A., Mosenzon O., Steg P.G., Davidson J.A., Nicolau J.C., Corbalan R., Hirshberg B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: Observations from the SAVOR-TIMI 53 Trial. Diabetes Care. 2015;38:696–705. doi: 10.2337/dc14-1850.
- Joo K.W., Kim S., Ahn S.Y., Chin H.J., Chae D.W., Lee J., Han J.S., Na K.Y. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol. 2013;14:98. doi: 10.1186/1471-2369-14-98.
- Tsuprykov O., Ando R., Reichetzeder C., von Websky K., Antonenko V., Sharkovska Y., Chaykovska L., Rahnenführer J., Hasan A.A., Tammen H., et al. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int. 2016;89:1049–1061. doi: 10.1016/j.kint.2016.01.016.
- Eun Lee J., Kim J.E., Lee M.H., Song H.K., Ghee J.Y., Kang Y.S., Min H.S., Kim H.W., Cha J.J., Han J.Y., et al. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab. Investig. 2016;96:547–560. doi: 10.1038/labinvest.2016.34.
- Chaykovska L., von Websky K., Rahnenführer J., Alter M., Heiden S., Fuchs H., Runge F., Klein T., Hocher B. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS ONE. 2011;6:e27861. doi: 10.1371/journal.pone.0027861.
- Dos Santos L., Salles T.A., Arruda-Junior D.F., Campos L.C.G., Pereira A.C., Barreto A.L.T., Antonio E.L., Mansur A.J., Tucci P.J.F., Krieger J.E., et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circul. Heart Fail. 2013;6:1029–1038. doi: 10.1161/CIRCHEARTFAILURE.112.000057.
- Arruda-Junior D.F., Martins F.L., Dariolli R., Jensen L., Antonio E.L., Dos Santos L., Tucci P.J., Girardi A.C. Dipeptidyl Peptidase IV Inhibition Exerts Renoprotective Effects in Rats with Established Heart Failure. Front. Physiol. 2016;7:293. doi: 10.3389/fphys.2016.00293.
- Gomez N., Touihri K., Matheeussen V., Mendes Da Costa A., Mahmoudabady M., Mathieu M., Baerts L., Peace A., Lybaert P., Scharpé S., et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur. J. Heart Fail. 2012;14:14–21. doi: 10.1093/eurjhf/hfr146.
- Salles T.A., dos Santos L., Barauna V.G., Girardi A.C.C. Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure. Int. J. Mol. Sci. 2015;16:4226–4249. doi: 10.3390/ijms16024226.
- Takashima S., Fujita H., Fujishima H., Shimizu T., Sato T., Morii T., Tsukiyama K., Narita T., Takahashi T., Drucker D.J., et al. Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy. Kidney Int. 2016;90:783–796. doi: 10.1016/j.kint.2016.06.012.
- Farah L.X., Valentini V., Pessoa T.D., Malnic G., McDonough A.A., Girardi A.C. The physiological role of glucagon-like peptide-1 in the regulation of renal function. Am. J. Physiol. Renal Physiol. 2016;310:F123–F127. doi: 10.1152/ajprenal.00394.2015.
- Holst J.J., Deacon C.F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48:612–615. doi: 10.1007/s00125-005-1705-7.
- Siragy H.M., Carey R.M. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am. J. Nephrol. 2010;31:541–550. doi: 10.1159/000313363.
- Remuzzi G., Perico N., Macia M., Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. 2005:S57–S65. doi: 10.1111/j.1523-1755.2005.09911.x.
- Ma T.K., Kam K.K., Yan B.P., Lam Y.Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br. J. Pharmacol. 2010;160:1273–1292. doi: 10.1111/j.1476-5381.2010.00750.x.
- Aroor A., Zuberek M., Duta C., Meuth A., Sowers J.R., Whaley-Connell A., Nistala R. Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. Int. J. Mol. Sci. 2016;17:780. doi: 10.3390/ijms17050780.
- Kawase H., Bando Y.K., Nishimura K., Aoyama M., Monji A., Murohara T. A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis. J. Mol. Cell Cardiol. 2016;98:37–47. doi: 10.1016/j.yjmcc.2016.06.066.
- Karmazyn M., Kilić A., Javadov S. The role of NHE-1 in myocardial hypertrophy and remodelling. J. Mol. Cell Cardiol. 2008;44:647–653. doi: 10.1016/j.yjmcc.2008.01.005.
- Filippatos G., Farmakis D., Parissis J. Renal dysfunction and heart failure: Things are seldom what they seem. Eur. Heart J. 2014;35:416–418. doi: 10.1093/eurheartj/eht515.
- Segall L., Nistor I., Covic A. Heart failure in patients with chronic kidney disease: A systematic integrative review. Biomed. Res. Int. 2014;2014:937398. doi: 10.1155/2014/937398.
- Sharkovska Y., Reichetzeder C., Alter M., Tsuprykov O., Bachmann S., Secher T., Klein T., Hocher B. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens. 2014;32:2211–2223. doi: 10.1097/HJH.0000000000000328.
- Pacheco B.P.M., Crajoinas R.O., Couto G.K., Davel A.P.C., Lessa L.M., Rossoni L.V., Girardi A.C.C. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J. Hypertens. 2011;29:520–528. doi: 10.1097/HJH.0b013e328341939d.
- Lim S.W., Jin L., Piao S.G., Chung B.H., Yang C.W. Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury. Lab. Investig. 2015;95:1174–1185. doi: 10.1038/labinvest.2015.93.
- Shigeta T., Aoyama M., Bando Y.K., Monji A., Mitsui T., Takatsu M., Cheng X.W., Okumura T., Hirashiki A., Nagata K., et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012;126:1838–1851. doi: 10.1161/CIRCULATIONAHA.112.096479.
- Lin C.H., Lin C.C. Sitagliptin attenuates inflammatory responses in lipopolysaccharide-stimulated cardiomyocytes via nuclear factor-κB pathway inhibition. Exp. Ther. Med. 2016;11:2609–2615. doi: 10.3892/etm.2016.3255.
- Picatoste B., Ramírez E., Caro-Vadillo A., Iborra C., Ares-Carrasco S., Egido J., Tuñón J., Lorenzo O. Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS ONE. 2013;8:e78330. doi: 10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287.
- Zhang H., Xiong Z., Wang J., Zhang S., Lei L., Yang L., Zhang Z. Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K/Akt/Bad signaling pathway. Mol. Med. Rep. 2016;13:1593–1601. doi: 10.3892/mmr.2015.4724.
- Balteau M., Van Steenbergen A., Timmermans A.D., Dessy C., Behets-Wydemans G., Tajeddine N., Castanares-Zapatero D., Gilon P., Vanoverschelde J.L., Horman S., et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2014;307:H1120–H1133. doi: 10.1152/ajpheart.00210.2014.
- Kanasaki K., Shi S., Kanasaki M., He J., Nagai T., Nakamura Y., Ishigaki Y., Kitada M., Srivastava S.P., Koya D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63:2120–2131. doi: 10.2337/db13-1029.
- Connelly K.A., Bowskill B.B., Advani S.L., Thai K., Chen L.H., Kabir M.G., Gilbert R.E., Advani A. Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease. Clin. Investig. Med. 2014;37:E172. doi: 10.25011/cim.v37i3.21384.
- Yamada H., Tanaka A., Kusunose K., Amano R., Matsuhisa M., Daida H., Ito M., Tsutsui H., Nanasato M., Kamiya H., et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: A subgroup analysis of the PROLOGUE study. Cardiovasc. Diabetol. 2017;16:63. doi: 10.1186/s12933-017-0546-2.
- Ferrario C.M. Cardiac remodelling and RAS inhibition. Ther. Adv. Cardiovasc. Dis. 2016;10:162–171. doi: 10.1177/1753944716642677.
- Zhang L.H., Pang X.F., Bai F., Wang N.P., Shah A.I., McKallip R.J., Li X.W., Wang X., Zhao Z.Q. Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT 2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart. Cardiovasc. Drugs Ther. 2015;29:243–255. doi: 10.1007/s10557-015-6592-7.
- Matsui H., Barry W.H., Livsey C., Spitzer K.W. Angiotensin II stimulates sodium-hydrogen exchange in adult rabbit ventricular myocytes. Cardiovasc. Res. 1995;29:215–221. doi: 10.1016/S0008-6363(96)88573-7.
- Girardi A.C.C., Knauf F., Demuth H.U., Aronson P.S. Role of dipeptidyl peptidase IV in regulating activity of Na +/H+ exchanger isoform NHE3 in proximal tubule cells. Am. J. Physiol. Cell Physiol. 2004;287:C1238–C1245. doi: 10.1152/ajpcell.00186.2004.
- Hori M., Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc. Res. 2009;81:457–464. doi: 10.1093/cvr/cvn335.
- Choi S.Y., Ryu H.M., Oh E.J., Choi J.Y., Cho J.H., Kim C.D., Kim Y.L., Park S.H. Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells. PLoS ONE. 2017;12:e0180393. doi: 10.1371/journal.pone.0180393.
- Choi S.H., Park S., Oh C.J., Leem J., Park K.G., Lee I.K. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation. Vascul. Pharmacol. 2015;73:11–19. doi: 10.1016/j.vph.2015.07.005.
- Koibuchi N., Hasegawa Y., Katayama T., Toyama K., Uekawa K., Sueta D., Kusaka H., Ma M., Nakagawa T., Lin B., et al. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc. Diabetol. 2014;13:157. doi: 10.1186/s12933-014-0157-0.
- Sauvé M., Ban K., Momen M.A., Zhou Y.Q., Henkelman R.M., Husain M., Drucker D.J. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59:1063–1073. doi: 10.2337/db09-0955.
- Suda M., Shimizu I., Yoshida Y., Hayashi Y., Ikegami R., Katsuumi G., Wakasugi T., Okuda S., Soga T., Minamino T. Inhibition of dipeptidyl peptidase-4 ameliorates cardiac ischemia and systolic dysfunction by up-regulating the FGF-2/EGR-1 pathway. PLoS ONE. 2017;12:e0182422. doi: 10.1371/journal.pone.0182422.
- Shimizu M.H., Coimbra T.M., de Araujo M., Menezes L.F., Seguro A.C. N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int. 2005;68:2208–2217. doi: 10.1111/j.1523-1755.2005.00677.x.
- Inoue B.H., Arruda-Junior D.F., Campos L.C.G., Barreto A.L.T., Rodrigues M.V., Krieger J.E., Girardi A.C.C. Progression of microalbuminuria in SHR is associated with lower expression of critical components of the apical endocytic machinery in the renal proximal tubule. Am. J. Physiol. Renal Physiol. 2013;305:F216–F226. doi: 10.1152/ajprenal.00255.2012.
- Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951;193:265–275.
- Ariyoshi M., Mizuno M., Morisue Y., Shimada M., Fujita S., Nasu J., Okada H., Shimomura H., Yamamoto K., Tsuji T. Identification of a target antigen recognized by a mouse monoclonal antibody to the bile canalicular surface of rat hepatocytes with a random phage display library. Acta Med. Okayama. 2002;56:187–191. doi: 10.18926/AMO/31684.
- Rutherford P.A., Pizzonia J.H., Biemesderfer D., Abu-Alfa A., Reilly R., Aronson P.S. Expression of Na(+)-H+ exchanger isoforms NHE1 and NHE3 in kidney and blood cells of rabbit and rat. Exp. Nephrol. 1997;5:490–497.
Source: PubMed